Cambridge, United Kingdom – 25 January 2018 –Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors. Dr Atkins has over 25 years’ experience as a global... Read more
The latest version of Sapientia™, v1.7, is to be released today (15th January 2018) bringing with it an array of infrastructure improvements, alongside three key new features: a simple and practical ACMG Guidelines interface, improved gene panel management and the first look at the automated interpretation request template. Version 1.7 is underpinned by a significant... Read more
Cambridge, UK, September 06, 2017 Congenica, a global provider of clinical genomics interpretation software, today announced a new customer partnership with the Coimbra Paediatric Hospital (CPH), a leading paediatric hospital in Portugal and part of the Coimbra Hospital and University Centre (CHUC). Through this partnership, the hospital has licensed Congenica’s Sapientia™ software platform to perform analysis of whole-exome sequencing data and... Read more
Commercial agreement with Congenica supports UniteGen’s goal of achieving the world’s largest human genome database Cambridge, UK – 21st June – Congenica’s Sapientia™ clinical genome analysis software platform will be used by China-based UniteGen to carry out whole genome sequencing (WGS) processing and analysis as part of China’s “100K Wellness Pioneer Project”, hosted by Beijing... Read more
CAMBRIDGE, UK and SAN DIEGO, USA – April 20, 2017 – Congenica and Edico Genome today announced the companies have partnered to offer their complementary platform technologies as an all-in-one, genome data analysis solution that accelerates clinical labs’ and hospitals’ progression from DNA sequencing to diagnosis for inherited diseases which otherwise takes months or years.... Read more
CAMBRIDGE, UK – 27 February, 2017 – Congenica, a leading provider of clinical genome analysis technology, announced today that it has raised £8m ($10m) in its Series B financing round. Existing investors, Cambridge Innovation Capital plc (CIC) and Amadeus Capital Partners (Amadeus) participated alongside new investor, Parkwalk Advisors (Parkwalk). Congenica will use the Series B... Read more